Increasing Incidence of Chronic Graft-versus-Host Disease in Allogeneic Transplantation: A Report from the Center for International Blood and Marrow Transplant.

Slides:

Advertisements

Similar presentations

National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis.

Advertisements

The Complex Relationship between Human Herpesvirus 6 and Acute Graft-versus-Host Disease Claire Pichereau, Kristell Desseaux, Anne Janin, Catherine Scieux,

Infection Rates among Acute Leukemia Patients Receiving Alternative Donor Hematopoietic Cell Transplantation Karen Ballen, Kwang Woo Ahn, Min Chen, Hisham.

Measuring Therapeutic Response in Chronic Graft-versus-Host Disease: National Institutes of Health Consensus Development Project on Criteria for Clinical.

Center for International Blood and Marrow Transplant Research Chronic Graft-versus- Host Disease Risk Score Predicts Mortality in an Independent Validation.

National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis.

Allogeneic Hematopoietic Cell Transplantation for Advanced Polycythemia Vera and Essential Thrombocythemia Karen K. Ballen, Ann E. Woolfrey, Xiaochun.

Yoshihiro Inamoto, Mary E. D

National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2014 Biomarker.

Allogeneic Transplantation with Reduced-Intensity Conditioning for Hodgkin and non- Hodgkin Lymphoma: Importance of Histology for Outcome Philippe Armand,

HLA Mismatch Is Associated with Worse Outcomes after Unrelated Donor Reduced- Intensity Conditioning Hematopoietic Cell Transplantation: An Analysis from.

Allogeneic Hematopoietic Cell Transplantation for Adult Chronic Myelomonocytic Leukemia Hien Duong Liu, Kwang Woo Ahn, Zhen-Huan Hu, Mehdi Hamadani,

Late Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation Aazim K. Omer, Daniel J. Weisdorf, Aleksandr Lazaryan,

Comparing Outcomes with Bone Marrow or Peripheral Blood Stem Cells as Graft Source for Matched Sibling Transplants in Severe Aplastic Anemia across Different.

Impact of Conditioning Regimen on Outcomes for Patients with Lymphoma Undergoing High-Dose Therapy with Autologous Hematopoietic Cell Transplantation

Marcelo C. Pasquini, Mei-Jie Zhang, Bruno C

Outcome of Transplantation for Myelofibrosis

Peripheral Blood Grafts from Unrelated Donors Are Associated with Increased Acute and Chronic Graft-versus-Host Disease without Improved Survival Mary.

Fluticasone, Azithromycin, and Montelukast Treatment for New-Onset Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation Kirsten.

Outcome and Prognostic Factors for Patients Who Relapse after Allogeneic Hematopoietic Stem Cell Transplantation Gita Thanarajasingam, Haesook T. Kim,

Impact of Age on Quality of Life, Functional Status, and Survival in Patients with Chronic Graft-versus-Host Disease Areej El-Jawahri, Joseph Pidala,

Impact of Ocular Chronic Graft-versus-Host Disease on Quality of Life

Clinical Benefit of Response in Chronic Graft-versus-Host Disease

Comparison of Short-Term Response and Long-Term Outcomes after Initial Systemic Treatment of Chronic Graft-Versus-Host Disease Paul J. Martin, Barry.

Recent Decrease in Acute Graft-versus-Host Disease in Children with Leukemia Receiving Unrelated Donor Bone Marrow Transplants Stella M. Davies, Dan.

National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: V. The 2014 Ancillary.

Cytomegalovirus Infection after Allogeneic Transplantation: Comparison of Cord Blood with Peripheral Blood and Marrow Graft Sources Christopher M. Walker,

Does Total Body Irradiation Conditioning Improve Outcomes of Myeloablative Human Leukocyte Antigen–Identical Sibling Transplantations for Chronic Lymphocytic.

A Comparison of Cyclophosphamide and Total Body Irradiation with Etoposide and Total Body Irradiation as Conditioning Regimens for Patients Undergoing.

The Sequence of Cyclophosphamide and Myeloablative Total Body Irradiation in Hematopoietic Cell Transplantation for Patients with Acute Leukemia Jennifer.

Prednisone (PDN)/Sirolimus (SRL) Compared to PDN/SRL/Calcineurin Inhibitor (CNI) as Treatment for Chronic Graft-Versus-Host-Disease (cGVHD): A Randomized.

Oral Chronic Graft-versus-Host Disease Scoring Using the NIH Consensus Criteria Nathaniel S. Treister, Kristen Stevenson, MS, Haesook Kim, Sook-Bin Woo,

Survival and Late Effects after Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancy at Less than Three Years of Age Lynda M. Vrooman,

Measuring Therapeutic Response in Chronic Graft-versus-Host Disease

Hospital Length of Stay in the First 100 Days after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia in Remission: Comparison among Alternative.

Allotransplantation for Patients Age ≥40 Years with Non-Hodgkin Lymphoma: Encouraging Progression-Free Survival Brian L. McClune, Kwang Woo Ahn, Hai-Lin.

Classifying Cytogenetics in Patients with Acute Myelogenous Leukemia in Complete Remission Undergoing Allogeneic Transplantation: A Center for International.

Betty K. Hamilton, Lisa Rybicki, Sally Arai, Mukta Arora, Corey S

Allogeneic Hematopoietic Cell Transplant for Prolymphocytic Leukemia

Comparative Analysis of Calcineurin Inhibitor–Based Methotrexate and Mycophenolate Mofetil–Containing Regimens for Prevention of Graft-versus-Host Disease.

Graft-versus-Host Disease Induced Graft-versus-Leukemia Effect: Greater Impact on Relapse and Disease-Free Survival after Reduced Intensity Conditioning

Unrelated Donor Allogeneic Transplantation after Failure of Autologous Transplantation for Acute Myelogenous Leukemia: A Study from the Center for International.

Sabina Kersting, Ronald J. Hené, Hein A. Koomans, Leo F. Verdonck

Comparison of Tacrolimus and Sirolimus (Tac/Sir) versus Tacrolimus, Sirolimus, and Mini-Methotrexate (Tac/Sir/MTX) as Acute Graft-versus-Host Disease.

Impact of Donor and Recipient Sex and Parity on Outcomes of HLA-Identical Sibling Allogeneic Hematopoietic Stem Cell Transplantation Alison W. Loren,

National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. The 2014 Clinical.

Comparison of Outcomes after Transplantation of G-CSF–Stimulated Bone Marrow Grafts versus Bone Marrow or Peripheral Blood Grafts from HLA-Matched Sibling.

Analysis of Gastrointestinal and Hepatic Chronic Grant-versus-Host Disease Manifestations on Major Outcomes: A Chronic Grant-versus-Host Disease Consortium.

Amphiregulin Modifies the Minnesota Acute Graft-Versus-Host Disease Risk Score: Results from BMT CTN Acute Gvhd Therapy Trials Shernan G. Holtan, Todd.

Outcomes of Human Leukocyte Antigen–Matched Sibling Donor Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia: Myeloablative Versus Reduced-

Chronic Graft-Versus-Host Disease (cGVHD) following Unrelated Donor Hematopoietic Stem Cell Transplantation (HSCT): Higher Response Rate In Recipients.

Reduced-Intensity Allogeneic Transplant in Patients Older Than 55 Years: Unrelated Umbilical Cord Blood Is Safe and Effective for Patients without a Matched.

HLA-Allele Matched Unrelated Donors Compared to HLA-Matched Sibling Donors: Role of Cell Source and Disease Risk Category Ann Woolfrey, Stephanie J.

Unrelated Donor Hematopoietic Cell Transplantation: Factors Associated with a Better HLA Match Jason Dehn, Mukta Arora, Stephen Spellman, Michelle Setterholm,

A Refined Risk Score for Acute Graft-versus-Host Disease that Predicts Response to Initial Therapy, Survival, and Transplant-Related Mortality Margaret.

Karen K. Ballen, Thomas R. Spitzer, Beow Y

Blood and Marrow Transplant Handbook

A Prognostic Score for Patients with Acute Leukemia or Myelodysplastic Syndromes Undergoing Allogeneic Stem Cell Transplantation Philippe Armand, Haesook.

Preengraftment Syndrome after Unrelated Cord Blood Transplant Is a Strong Predictor of Acute and Chronic Graft-versus-Host Disease Haydar Frangoul, Li.

A Bortezomib-Based Regimen Offers Promising Survival and Graft-versus-Host Disease Prophylaxis in Myeloablative HLA-Mismatched and Unrelated Donor Transplantation:

Effect of Postremission Therapy before Reduced-Intensity Conditioning Allogeneic Transplantation for Acute Myeloid Leukemia in First Complete Remission

One-Antigen Mismatched Related versus HLA-Matched Unrelated Donor Hematopoietic Stem Cell Transplantation in Adults with Acute Leukemia: Center for International.

The Impact of Graft-versus-Host Disease on the Relapse Rate in Patients with Lymphoma Depends on the Histological Subtype and the Intensity of the Conditioning.

Outcomes of Allogeneic Hematopoietic Cell Transplantation for Adolescent and Young Adults Compared with Children and Older Adults with Acute Myeloid Leukemia

Reduced-Intensity Conditioning for Unrelated Donor Progenitor Cell Transplantation: Long-Term Follow-Up of the First 285 Reported to the National Marrow.

Pulmonary Symptoms Measured by the National Institutes of Health Lung Score Predict Overall Survival, Nonrelapse Mortality, and Patient-Reported Outcomes.

Classification of HLA-Matching for Retrospective Analysis of Unrelated Donor Transplantation: Revised Definitions to Predict Survival Daniel Weisdorf,

Reduced-Intensity Conditioning Stem Cell Transplantation: Comparison of Double Umbilical Cord Blood and Unrelated Donor Grafts Yi-Bin Chen, Julie Aldridge,

HLA-Mismatch Is Associated with Worse Outcomes after Myeloablative Conditioning and Unrelated Donor Hematopoietic Cell Transplantation: A Cibmtr Analysis

In Memoriam: E. Donnall Thomas

Presentation transcript:

Increasing Incidence of Chronic Graft-versus-Host Disease in Allogeneic Transplantation: A Report from the Center for International Blood and Marrow Transplant Research Sally Arai, Mukta Arora, Tao Wang, Stephen R. Spellman, Wensheng He, Daniel R. Couriel, Alvaro Urbano-Ispizua, Corey S. Cutler, Andrea A. Bacigalupo, Minoo Battiwalla, Mary E. Flowers, Mark B. Juckett, Stephanie J. Lee, Alison W. Loren, Thomas R. Klumpp, Susan E. Prockup, Olle T.H. Ringdén, Bipin N. Savani, Gérard Socié, Kirk R. Schultz, Thomas Spitzer, Takanori Teshima, Christopher N. Bredeson, David A. Jacobsohn, Robert J. Hayashi, William R. Drobyski, Haydar A. Frangoul, Görgün Akpek, Vincent T. Ho, Victor A. Lewis, Robert Peter Gale, John Koreth, Nelson J. Chao, Mahmoud D. Aljurf, Brenda W. Cooper, Mary J. Laughlin, Jack W. Hsu, Peiman Hematti, Leo F. Verdonck, Melhelm M. Solh, Maxim Norkin, Vijay Reddy, Rodrigo Martino, Shahinaz Gadalla, Jenna D. Goldberg, Philip L. McCarthy, José A. Pérez-Simón, Nandita Khera, Ian D. Lewis, Yoshiko Atsuta, Richard F. Olsson, Wael Saber, Edmund K. Waller, Didier Blaise, Joseph A. Pidala, Paul J. Martin, Prakash Satwani, Martin Bornhäuser, Yoshihiro Inamoto, Daniel J. Weisdorf, Mary M. Horowitz, Steven Z. Pavletic Biology of Blood and Marrow Transplantation Volume 21, Issue 2, Pages 266-274 (February 2015) DOI: 10.1016/j.bbmt.2014.10.021 Copyright © 2015 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 1 In the multivariate analysis, higher risk of cGVHD in the most recent time period (2004-2007 versus 1995-1999: OR = 1.19, P < .0001; and 2004-2007 versus 2000-2003: OR = 1.13, P = .002). Biology of Blood and Marrow Transplantation 2015 21, 266-274DOI: (10.1016/j.bbmt.2014.10.021) Copyright © 2015 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 2 Increased cGVHD incidence when stratified by (A) donor type (HLA identical sibling: HR = 1.17; unrelated donor: HR = 1.07; cord blood: HR = 1.24, all P < .01), (B) graft type (PBSC: HR = 1.19; cord blood: HR = 1.24, P < .01), or (C) conditioning intensity (myeloablative: HR = 1.13; reduced intensity: HR = 1.16, P < .01). Biology of Blood and Marrow Transplantation 2015 21, 266-274DOI: (10.1016/j.bbmt.2014.10.021) Copyright © 2015 American Society for Blood and Marrow Transplantation Terms and Conditions